Abstract The Philadelphia (Ph) chromosome, resulting from the t (9; 22)(q34; q11)
translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of …

Evidence-based recommendations have been established for treatment of chronic myeloid
leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this …

Background All studies of treatment-free remission (TFR) in patients with chronic myeloid
leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have …

Purpose: Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic
myelogenous leukemia (CML) management and several studies have demonstrated the …

There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic
phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Chronic myeloid leukemia (CML) is a chronic disease resulting in myeloid cell expansion
through expression of the BCR-ABL1 fusion transcript. Tyrosine kinase inhibitors (TKI) have …

Subsequent to the development and global availability of BCR/ABL–targeted tyrosine kinase
inhibitors (TKIs), the prognosis of patients with chronic myeloid leukemia (CML), at least …

Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid
leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML adult …